Abeona Therapeutics (PCJ) Price & Analysis
PCJ Stock Chart & Stats
- Day’s Range
- EUR 4.01 - EUR 4.01
- 52-Week Range
- EUR 3.56 - EUR 7.08
- Previous Close
- EUR 4.02
- Volume
- 0
- Average Volume (3M)
- 40
- Market Cap
- EUR 221.99M
- Enterprise Value
- EUR 225.61M
- Total Cash (Recent Filing)
- EUR 146.83M
- Total Debt (Recent Filing)
- EUR 19.87M
- Price to Earnings (P/E)
- ―
- Beta
- 1.13
- Next Earnings
- Nov 16, 2026
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Adoption
Rising treatment volume and sequential revenue growth show that ZEVASKYN is moving beyond development into early commercial adoption. Continued patient uptake can broaden physician experience, improve operating learning, and support a more durable revenue base as additional treatment centers become productive.
Reimbursement Support
The NTAP award provides supplemental hospital reimbursement and strengthens the commercial infrastructure supporting ZEVASKYN adoption. As a regulatory and reimbursement milestone, it can reduce payer friction, reinforce the therapy’s clinical value proposition, and support treatment access over multiple quarters.
Liquidity And Leverage
A sizable cash and investment balance combined with modest leverage gives Abeona financial flexibility while it expands commercialization. This liquidity can fund treatment-center development and operating needs, while the relatively low debt burden limits fixed repayment pressure during the ongoing transition toward profitability.
Bears Say
Persistent Unprofitability
Abeona’s commercial progress has not yet translated into sustainable earnings or cash generation. Large operating and free-cash-flow deficits require substantial funding for continued operations, leaving the company exposed to financing dependence unless revenue scales and expenses narrow materially.
Manufacturing Yield Risk
Manufacturing failures can create a direct gap between patients treated and revenue recognized, while Abeona still absorbs the associated production costs. Repeated yield or specification problems could weaken gross-margin improvement, disrupt patient scheduling, and make the commercial revenue ramp less predictable.
Operational Execution Complexity
The short product shelf life makes delivery dependent on tightly coordinated biopsy, manufacturing, hospital, and treatment steps. This complexity can constrain throughput as the network grows, increase the risk of canceled or delayed procedures, and slow the conversion of activated centers into recurring revenue.
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
What is Abeona Therapeutics’s market cap?
When is Abeona Therapeutics’s upcoming earnings report date?
How were Abeona Therapeutics’s earnings last quarter?
Is Abeona Therapeutics overvalued?
Does Abeona Therapeutics pay dividends?
What is Abeona Therapeutics’s EPS estimate?
How many shares outstanding does Abeona Therapeutics have?
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Abeona Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Abeona Therapeutics Stock Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vishwas Seshadri
- Employees
- 226
- Website
- www.abeonatherapeutics.com
- Address
- 6555 Carnegie Avenue, Cleveland, OH, 44103, US
Abeona Therapeutics (PCJ) Earnings & Revenues
PCJ Earnings Call
Earnings Call SentimentNeutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.
View all DE:PCJ earnings summariesPCJ Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 4 | 0 | 8 |